SuperworthAlnylam Pharmaceuticals free cash flow ALNY
Cash from operations less capital spending, by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $793.9M
- Latest quarter, Q2 FY26
- $292M
- +153% on a year earlier
- Fiscal year 2025
- $439.5M
Alnylam Pharmaceuticals' free cash flow was $793.9M over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $292M, up 153% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $439.5M | n/a |
| FY2024 | −$42.6M | −202% |
| FY2023 | $41.9M | n/a |
| FY2022 | −$613.3M | n/a |
| FY2021 | −$718.1M | n/a |
| FY2020 | −$685.3M | n/a |
| FY2019 | −$418.6M | n/a |
| FY2018 | −$689.5M | n/a |
| FY2017 | −$487M | n/a |
| FY2016 | −$372.3M | n/a |
| FY2015 | −$202.1M | n/a |
| FY2014 | −$174.6M | n/a |
| FY2013 | −$72.7M | n/a |
| FY2012 | −$124M | n/a |
| FY2011 | −$88.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $292M | +153% | $793.9M | |
| Q1 FY26 | $48.7M | n/a | $617.4M | |
| Q4 FY25 | $140.3M | n/a | $439.5M | |
| Q3 FY25 | $313M | +692% | $195.4M | |
| Q2 FY25 | $115.5M | −1% | −$78M | |
| Q1 FY25 | −$129.3M | n/a | −$77.4M | |
| Q4 FY24 | −$103.8M | n/a | −$42.6M | |
| Q3 FY24 | $39.5M | −88% | $16.1M | |
| Q2 FY24 | $116.1M | n/a | $318.9M | |
| Q1 FY24 | −$94.5M | n/a | $127.8M | |
| Q4 FY23 | −$45.1M | n/a | $41.9M | |
| Q3 FY23 | $342.3M | n/a | −$66.6M |
Against its peers
Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| ALNYAlnylam Pharmaceuticals | 2.6% |
| UTHRUnited Therapeutics | 4.3% |
| INCYIncyte | 8.2% |
| ONCBeOne Medicines | 3.1% |
| EXELExelixis | 7.3% |
| NBIXNeurocrine Biosciences | 6.0% |
| HALOHalozyme Therapeutics | 5.7% |
| TECHBIO-TECHNE | 2.3% |
| REGNRegeneron Pharmaceuticals | 4.5% |
| RGENRepligen | 1.1% |
| KRYSKrystal Biotech | 2.8% |
| Peer median | 4.4% |
Where Alnylam Pharmaceuticals ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Alnylam Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.